Precipio Inc (PRPO)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-05
$18.59-5.01%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-05
QuarterlyIQ Insights · PRPO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -58.5% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 35.9% |
Growth built into the price is above our model estimate.
The price assumes 94.4 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 19 industry peers
Why it matters: Q2 brought in $0.7 million from operations and ended with over $3 million in cash. A cash drop could weaken the story.
Watch forThe Q3 results show operating cash flow above $0 and an ending cash balance above $3 million.
Also watch forThe Q3 results show operating cash flow below $0 or an ending cash balance below $3 million.
Why it matters: Management plans to discuss 2027 and beyond. Specific targets can be checked against later results.
Watch forThe Nov. 10 call sets a numeric 2027 target for revenue, product sales, or cash generation.
Also watch forThe call gives no numeric 2027 target, or gives one below Q2's $7.021 million quarterly revenue.
Why it matters: Management said product revenue passed an important milestone. A clear amount would show how much this business has grown.
Supportive ifOn Nov. 10, management names the milestone and reports product revenue above Q2's $0.9 million.
Worry ifThe Nov. 10 call gives no amount, or reports product revenue at or below Q2's $0.9 million.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$222 on $10,000 · ±2.2% | How much price usually moves either way. |
| Bad day | $636 loss on $10,000 · 6.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,504 loss on $10,000 · 45.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.